CASTIA Neurological Core Imaging Lab (NCIL)

Sponsor: Sanofi-Aventis Group

Location(s): United States


CASTIA—Clopidogrel in Acute Stroke and TIA

Can acute antiplatelet treatment make a difference in stroke recurrence? Clopidogrel in Acute Stroke and TIA (CASTIA) will randomize a projected 2400 patients with acute, minor ischemic stroke or TIA within the first 24 hours of symptom onset; all patients will be treated with aspirin, 75 mg/day, and will also receive either placebo or clopidogrel at an initial loading dose of 300 mg/day followed by main- tenance at 75 mg/day.10,19,20 Primary composite outcome will include stroke, new infarction documented by MRI, MI, and vascular death at 90 days of follow-up.